Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Inhibitors of the mechanistic target of rapamycin (mTOR) hold promise for treatment of hematological malignancies. Analogs of the allosteric mTOR inhibitor rapamycin are approved for mantle cell lymphoma but have limited efficacy in other blood cancers. ATP-competitive "active-site" mTOR i...

Full description

Bibliographic Details
Main Authors: Sharmila Mallya, Briana A Fitch, J Scott Lee, Lomon So, Matthew R Janes, David A Fruman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3931643?pdf=render

Internet

http://europepmc.org/articles/PMC3931643?pdf=render

Similar Items